|

Identification of Hepatic Fibrosis Using 4D-MRI

RECRUITINGN/ASponsored by University Hospital, Basel, Switzerland
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Basel, Switzerland
Started2021-08-01
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05385237

Summary

To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. 4D-MRI allows to overcome the limitations of currently used techniques. Hence, 4D-MRI may help to identify a novel biomarker for non-invasive staging of liver fibrosis , and therefore improve the final diagnosis of patients suffering from liver diseases.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* age ≥ 18 years
* (a) Patients with histologically confirmed chronic liver disease, including NAFLD, ALD, viral hepatitis B and C, genetic (e.g. Wilson disease, hemochromatosis) or autoimmune liver disease
* (b) Patients with acute liver inflammation or cardiac blood congestion to the liver (as assessed by laboratory values, imaging findings and clinical history)
* ability to understand and consent to participate in this study

Exclusion Criteria:

* Medical implant like cardiac pacemaker, pump, hip prosthesis
* Metallic objects in the body (e.g. splinters after an accident)
* Persons who have undergone brain or cardiac surgery
* Claustrophobia
* Body Weight \>140kg or as provided by the MR manufacturer
* Pregnant and lactating women
* (a) Active hepatocellular carcinoma (HCC) (remark: patients with a history of HCC and curative treatment can be included)
* (a) CHILD C cirrhosis
* (a) and (b) Patients with overt ascites (except if they respond to diuretic treatment and the ascites resolves)
* (c) Metabolic syndrome, BMI \>30 kg/m2
* (c) Acute or chronic liver disease
* Patients not willing or able to give a written informed consent

Conditions2

Liver DiseaseLiver Diseases

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.